SINGULAIR
Total Payments
$145,427
Transactions
4
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $111,182 | 2 | 0 |
| 2017 | $34,245 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $145,427 | 4 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Oral Bacterial Extracts for Asthma Prevention ORBEX | Merck Sharp & Dohme Corporation | $145,427 | 0 |
Top Doctors Receiving Payments for SINGULAIR
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Tucson, AZ | $145,427 | 4 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $145,427
Product Information
- Type Drug
- Total Payments $145,427
- Total Doctors 0
- Transactions 4
About SINGULAIR
SINGULAIR is a drug associated with $145,427 in payments to 0 healthcare providers, recorded across 4 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2018. In 2018, $111,182 was paid across 2 transactions to 0 doctors.
The most common payment nature for SINGULAIR is "Unspecified" ($145,427, 100.0% of total).
SINGULAIR is associated with 1 research study, including "Oral Bacterial Extracts for Asthma Prevention ORBEX" ($145,427).